Compare Bit Digital Inc (BTBT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bit Digital Inc vs BIO-TECHNE Corp — how do they compare? Bit Digital Inc trades at $1.35 (market cap $453.60M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 24.8× Bit Digital Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| BTBT | TECH | |
|---|---|---|
Market Cap | $453.60M | $11.24B |
Sector | Technology | Health |
52-Week High | $4.22 | $72.29 |
52-Week Low | $1.23 | $43.31 |
Enterprise Value | $742.91M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.38 with a 1.1% daily gain, showing modest momentum despite a bearish technical signal from moving averages. The company reported revenue of $113.56M in 2025 but posted a significant net loss of $80.32M, with profitability metrics like ROE at -38.98% indicating financial strain. Analyst coverage remains limited but unanimously positive, with 2 buy ratings and no hold or sell recommendations. Recent news highlights upcoming Q2 2026 earnings and mixed price target discussions.
The outlook for BTBT is clouded by persistent losses and negative cash flow from operations, though financing activities provide liquidity. Investment opportunities hinge on a potential earnings turnaround, while risks include sustained unprofitability, competitive pressures, and reliance on external funding. The stock's low valuation multiples may attract value seekers, but caution is warranted given the fundamental challenges.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
